Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Role of Cagrilintide in Bone Metabolism During Weight Loss in Postmenopausal Women With Obesity
NCT07010432Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Jun 2025
- Primary completion
- May 2028
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cagrilintide in obesity (4 arms), sponsored by Novo Nordisk. Primary endpoint: Relative change in volumetric bone mineral density of the total hip at 68 weeks. Started Jun 2025; status: recruiting.
02
Drugs
cagrilintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07010432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07010432.